American Association for Cancer Research
Browse

sorry, we can't preview this file

crc-22-0208-s02.docx (13.54 kB)

Table TS2 from Loss of the Volume-regulated Anion Channel Components LRRC8A and LRRC8D Limits Platinum Drug Efficacy

Download (13.54 kB)
journal contribution
posted on 2023-04-04, 01:43 authored by Carmen A. Widmer, Ismar Klebic, Natalya Domanitskaya, Morgane Decollogny, Denise Howald, Myriam Siffert, Paul Essers, Zuzanna Nowicka, Nadine Stokar-Regenscheit, Marieke van de Ven, Renske de Korte-Grimmerink, José A. Galván, Colin E.J. Pritchard, Ivo J. Huijbers, Wojciech Fendler, Conchita Vens, Sven Rottenberg

Primer sequences used for Lrrc8a or Lrrc8d knockout control in 2D cell lines or Lrrc8d knockout mice or reconstitution experiments

Funding

Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (SNF)

EC | ERC | HORIZON EUROPE European Research Council (ERC)

Krebsliga Schweiz (Swiss Cancer League)

Wilhelm Sander-Stiftung (Wilhelm Sander Foundation)

History

ARTICLE ABSTRACT

We demonstrate that lack of expression of Lrrc8a or Lrrc8d significantly reduces the uptake and efficacy of cisplatin and carboplatin in Pt-sensitive BRCA1;p53-deficient tumors. Moreover, our work provides support to confirm the LRRC8A and LRRC8D gene expression in individual tumors prior to initiation of intensive Pt-based chemotherapy.

Usage metrics

    Cancer Research Communications

    Categories

    Keywords

    BiomarkersBreast CancerDrug ResistanceHead, Neck & Oral CancersChemotherapyPrecision Medicine

    Licence

    CC BY

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC